Investigational Use of Meningococcal Serogroup B Vaccine
Investigational Use of Meningococcal Serogroup B Vaccine
The availability of a vaccine for N. meningitidis serogroup B is a significant advance in reducing the impact of sepsis and meningitis worldwide. While not yet approved by the FDA, the availability of this vaccine as an investigational product during outbreaks at two U.S. universities has demonstrated its benefit in controlling the spread of disease.
Summary
The availability of a vaccine for N. meningitidis serogroup B is a significant advance in reducing the impact of sepsis and meningitis worldwide. While not yet approved by the FDA, the availability of this vaccine as an investigational product during outbreaks at two U.S. universities has demonstrated its benefit in controlling the spread of disease.
Source...